Characteristics of circulating endothelial cells obtained from non-ST-segment elevation myocardial infarction patients with additional diastolic dysfunction of left ventricle observed in echocardiography by Burchardt, Pawel et al.
Address for correspondence: Pawel Burchardt, PhD, MD, MSc, FESC, Biology of Lipid Disorders Department, Chair of  
Biology and Environmental Sciences, Poznan University of Medical Sciences; Department of Cardiology, J. Strus Hospital, 
ul. Szwajcarska 3, 61–285 Poznań, Poland, tel: +48 618739333, fax: +48 618739333, e-mail: pab2@tlen.pl
Received: 19.01.2018 Accepted: 4.09.2018
Characteristics of circulating endothelial cells  
obtained from non-ST-segment elevation myocardial 
infarction patients with additional diastolic  
dysfunction of left ventricle observed  
in echocardiography
Pawel Burchardt1, 2, 3, Maura Farinacci4, Magdalena Mayer5,  
Klaus Luecke6, Thomas Krahn7, Jaroslaw Manczak2,  
Marek Slomczynski2, Jaroslaw Hiczkiewicz3, Janusz Rzezniczak2
1Biology of Lipid Disorders Department, Chair of Biology and Environmental Sciences,  
Poznan University of Medical Sciences, Poznan, Poland  
2Department of Cardiology, J. Strus Hospital, Poznan, Poland 
3Department of Cardiology, Hospital of Nowa Sol, Poland 
4Institute for Medical Immunology, Berlin-Brandenburg Center für Regenerative Therapies,  
Core Unit Biomarker, Charité University Medicine Berlin, Germany 
5Zablab sp. z o.o, Poznan, Poland  
6HaimaChek Inc., Santa Monica, CA, United States 
7Bayer AG, Biomarker Research, Berlin, Germany
Abstract
Background: Circulating endothelial cells (CEC) may be used to find new strategies for the early di-
agnosis of cardiovascular diseases. The major objective of the project is to broaden knowledge of CEC 
biology by determining their phenotypic characteristics. The additional aim is to clarify whether on the 
basis of these information it is possible to identify the origin of CEC release (from various cardiovas-
cular compartments).
Methods: Circulating endothelial cells were collected from arterial blood prior to angiography, as well 
as from arterial and venous blood obtained after angiography/coronary angioplasty, from 18 patients 
with non-ST-segment elevation myocardial infarction (NSTEMI). CECs were quantified by flow cy-
tometry and defined as Syto16 (dye)+, CD45dim/neg, CD31+ and CD146+. The additional CD36+ was 
establish as a marker of endothelial cells released from small vessels of the microcirculation. 
Results: The total number of CECs increased significantly after the percutaneous transluminal coro-
nary angioplasty (PTCA) in the arterial system. Number of CECs isolated at similar time points (after 
invasive procedure) did not differ significantly between arteries and veins, but the number of CD36+ 
CECs after coronary angioplasty was significantly higher in the venous system, than in the arterial system.
Conclusions: The number of CD36+ in artery samples obtained after coronary angioplasty (PTCA) had 
tendency to be decreased (in comparison to the sample obtained before angiography). It was major difference 
between those who had PTCA performed vs. those who had not. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
The Holy Grail in cardiology is to ‘predict 
the unpredictable’. This means, that 50% of all 
new cases of ischemic heart disease (IHD) occur 
as myocardial infarction or sudden cardiac death 
[1–7]. It is strange, but there are no clinical tools 
to predict and avoid these episodes. Neither can 
new cardio-vascular episodes be predicted among 
those who suffer from  the established IHD [1].
Circulating endothelial cells (CEC) may be 
used to find early and new strategies for the diag-
nosis of cardiovascular diseases [8–13]. They are 
released into the blood due to reduced adhesion to 
the vessels basement membrane (VBM) as a result 
of mechanical injury, necrosis or apoptosis [8, 13, 
14]. Very little is known about the CEC phenotype, 
which may depend on their state of activation, way 
of release, vascular beds they originate from or the 
caliber of the vessel from which they are derived. 
The isolation and determination of CEC phenotype 
may allow, in combination with troponin assess-
ment, for more sophisticated diagnosis of patients 
with acute coronary syndrome (ACS), as well as to 
distinguish from this group subjects with impaired 
coronary microcirculation. Additionally, it could 
be possible that based on the assessment of CEC 
phenotype, patients who are at risk for a new or 
another cardiovascular event would be identified.
Owing to the above, it was decided to focus 
on a cohort with a new onset of coronary artery 
disease in shape of ACS (with no history of cardio-
vascular events). The CECs level can be increased 
in all ACS patients, but the most pleasant objects 
for CEC studies are subjects with non-ST-segment 
elevation myocardial infarction (NSTEMI). The 
first reason is the wide variety of CEC sources 
(large epicardial CEC, microvascular CEC’s) and 
the mechanisms leading to their release, i.e. me-
chanical injury and microvascular disturbances. 
Secondly, the fact that according to European 
Society of Cardiology (ESC) guidelines more time 
is possible for clinical evaluation of NSTEMI pa-
tients before the decision to perform the diagnostic 
angiography to be done.
The purpose of the study is to:
 — find differences in number of CECs between 
subjects who underwent percutaneous trans-
luminal coronary angioplasty (PTCA) and 
those who did not;
 — find quantitative differences between CECs 
depending on vascular beds that they are 
derived from (venous system vs. arterial 
system);
 — establish the origin of isolated CECs depend-
ing on the compartment of arterial system of 
origin (artery vs. microcirculation);
 — find differences in the amount of CECs isolated 
from the arterial system, depending on the way 
of their release before and after mechanical 
injury, (i.e. before and after PTCA).
Methods
Patients and study design
The study was carried out at the Department 
of Cardiology of J. Strus Hospital, Poznan, Poland 
between 2014 and 2016. Protocol was conducted 
according to guidelines stated in the Declaration 
of Helsinki and was approved by the local bioethics 
commission. All subjects were informed about the 
aim of the study and gave their written consent.
The study group consisted of patients suffer-
ing from ACS/NSTEMI/their first cardiovascular 
episode ever. The additional inclusion criteria was 
an impaired left ventricular (LV) diastolic function 
in echocardiography. Left diastolic dysfunction 
was defined when all echocardiographic features 
at admission were observed: E/A < 1, e’/a’ < 1 
from lateral wall, isovolumetric relaxation time > 
0.1 s, deceleration time of wave E was > 0.15 s. 
Patients were qualified for an acute coronary 
angiography (due to the ACS guidelines). Research 
material was arterial blood obtained before angiog-
raphy (when the arterial sheet was fixed) and after 
coronary angiography/angioplasty (blood was col-
lected from the arterial sheet before it was released 
after the invasive procedure). The last, venous 
blood collection was done from the ulnar vein. It 
was performed strictly 30 min after removing the 
arterial sheet after the angiography/angioplasty. 
The exclusion criteria was lack of diastolic 
dysfunction in ACS/NSTEMI subjects, observed 
in screening echocardiography before diagnostic 
coronary angiography. 
Coronary angiography was performed no later 
than 24 h after admission, in accordance with the 
ESC guidelines for management in NSTEMI.
The study was organized in three phases:
 — selection of 18 patients with appropriate clini-
cal characteristics;
 — identification and quantification of CECs and 
microvascular CEC (mvCECs) using flow 
cytometry;
 — statistical analysis of collected data.
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CEC quantification and characterization  
by flow cytometry
Circulating endothelial cells were detected 
by flow cytometry using a panel of monoclonal 
antibodies and nuclear staining Syto16. CECs were 
defined as DNA+, CD45dim, CD31+ and CD146+. 
mvCECs were identified as CD36+ CEC. In the 
staining procedure, whole blood samples (500 µL) 
were incubated with FcR blocking Reagent (Milt-
enyi) for 15 min at 4°C, and then with the respec-
tive antibody mixtures for 40 min at 4°C. After red 
cell lysis with High-Yield Lyse (Life technologies) 
for 15 min at room temperature, samples were cen-
trifuged and resuspended in FACS buffer (PBS+ 
0.5% BSA + 0.5 mM EDTA + 0.05% NaN3). Due 
to high variability associated with the detection 
of cell populations with low frequency, samples 
were stained and measured in triplicate. Acquisi-
tion was done using a LSR II Flow Cytometer 
(BD Biosciences), equipped with 488-, 633-, and 
405-nm lasers. Flow cytometer setup and cali-
bration were performed using CS&T beads (BD 
Biosciences). For sample acquisition, mononuclear 
cells (PMNCs) were set as the stopping gate with 
a threshold of 5 × 105 PMNCs. Data was acquired 
using FACSDiva 6.0 Software (BD Biosciences) 
and data analysis was performed using Flowjo 10. 
Fluorescence compensation was performed by us-
ing BD™ CompBeads Set Anti-Mouse Ig. CECs and 
EPCs levels were first calculated as a percentage 
of PMNC. Absolute counts (cells/mL) were then 
determined by multiplying the CEC or EPC per-
centage of the PMNC by the absolute PMNC count 
obtained in separate tubes by using Flow-Count™ 
Fluorospheres (Beckmann Coulter).
Laboratory tests
Laboratory tests were performed using com-
mercially available diagnostic kits. The serum 
creatinine concentration was determined by Jaffe’s 
reaction using Roche Cobas C (Hitachi, Germany). 
Creatinine clearance and glomerular filtration rate 
were estimated using formulas from Cockroft-
Gault. Potassium and sodium concentrations were 
determined by potentiometry using the Cobas 
System 6000 (Roche Diagnostics, Germany). As-
sessments of peripheral blood counts were per-
formed using Sysmex XT2000i, the US system. 
Concentration of urea, uric acid, total cholesterol, 
triglycerides and high-density lipoproteins were 
quantified using enzymatic colorimetric method 
(Cobas C Roche/Hitachi, Germany) with specific 
reagents. The concentration of low-density lipopro-
teins was calculated using the Friedewald formula.
Statistical analysis
After applying the Shapiro-Wilks test to deter-
mine a normal distribution of data, noncategorical data 
distributed normally was expressed as mean (SD) 
and data distributed non-normally was expressed as 
median (interquartile range [IQR]). The Student t-
test was used for variables with normal distribution 
(for two independent and dependent variables). The 
Mann-Whitney U test (for two independent variables) 
and the Sign test as well as the Wilcoxon matched 
pairs test (for two dependent variables) were used 
for variables without normal distribution. Statistical 
significance was set at p < 0.05. The correlation be-
tween variables showing a normal distribution was 
evaluated with the Pearson coefficient, whereas the 
Spearman rang correlation coefficient was applied for 
variables with a non-normal distribution. All analyses 
were performed with STATISTICA 7.0 (Statsoft, 
USA) and SPSS-20 (IBM, USA).
Results
Demographic data
The study group consisted of 18 patients (14 
males, 4 females) with a median age of 66.6 (60–73) 
years with NSTEMI, and with additional echocar-
diographic features of LV diastolic dysfunction; 
moreover, this was their first episode of cardio-
vascular disease. The median body mass index of 
the study group was 24.7 (22.6-28.7) kg/m2. Each 
patient received pharmacotherapy before index 
hospitalization. The clinical, biochemical and de-
mographic characteristics are provided in Table 1.
Coronary artery angiography was performed 
in all patients and additional coronary angioplasty 
was performed in 14 (77.8%) cases. Among the 
patients who underwent angioplasty, 5 (27.8%) 
had stents placed in the left descending artery, 
3 (16.7%) in left circumflex artery and 1 (5.5%) in 
left intermedia artery. One patient received stents 
to both the left circumflex and left intermedia ar-
tery. The right coronary artery had been stented 
in 4 (22.2%) subjects.
During hospitalization patients received an-
giotensin converting enzyme inhibitors (75% of 
the subjects), angiotensin receptor blockers (10% 
of the subjects), beta-blockers in (85% of the 
subjects), statins (100% of the subjects), diuret-
ics (20% of the subjects), and mineralocorticoid 
receptor antagonists (10% of the subjects).
Echocardiographic characteristics 
The echocardiographic parameters at hospital 
admission are provided in Table 2. LV diastolic 
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dysfunction (inclusion criteria) at various levels 
of severity were present in all patients.
There was no significant improvement ob-
served in diastolic function in echocardiography 
the following day, subsequent to angiography (or 
coronary artery angioplasty following ACS) (data 
not provided).
Characterization of CECs present before 
angiography in radial artery, and after  
coronary angiography/angioplasty  
in radial artery and brachial vein
Characteristics and levels of CECs obtained 
in the studied groups are shown in Table 3. The 
number of CECs after the angiography/angioplasty 
increased in the arterial system in the whole group. 
In the venous system, although observed CEC 
cell numbers were highest, differences were not 
statistically significant. The number of CD36+ 
(microvascular) cells after coronary angiography/
angioplasty did not change significantly in the ar-
terial system, but was significantly higher in vein, 
although the blood was collected during a similar 
period following an invasive cardiac procedure (30 
min after the invasive procedure).
A comparison between subjects who had coro-
nary angioplasty performed vs. those who did not 
(in artery before and after angiography and artery 
vs. vein after angioplasty) is provided in Table 4. 
The number of CEC, CEC per 106 PMNC, the per-
centage of mvCEC on total CECs, measured before 
and after angiography in artery (as well as before 
Table 1. Biochemical, clinical and demographic characteristics of patients at hospital admission.
Median Percent Interquartile range
Laboratory parameter
RBC [106/µL] 4.4 4.2–4.7
HGB [g/dl] 13.8 12.6–14.7
HCT [%] 39.8 38.2–42.5
WBC [103/µL] 7.1 6.2–8.5
K+ [mmol/L] 4.2 3.8–4.47
TSH [uIU/mL] 1.1 0.7–2.1
TC [mmol/L] 4.9 4.5–5.8
LDL [mmol/l] 3.1 2.2–4.1
HDL [mmol/L] 1.3 1.1–1.4
TG [mmol/L] 1.6 1.1–1.8
CRP [mg/L] 1.7 1.1–5.5
BNP [pg/mL] 89.6 49.3–221.5
Creatinine [µmol/L] 94 79–105
ALAT [U/L] 19 15–29
Tn max [ng/L] 2645 1910–4244
Radiology parameter
Mean time of coronary angiography + PTCA [min] 27.7 17–34
The balloon inflation time during angioplasty [s] 25 12.5–30
Number of patients with performed PTCA = 14
Average number of implanted stent per patient = 1.14
Demographic data
Dysglicemia (IFG, IGT, diabetes) 65%
Dyslipidemia 55%
Hypertension 55%
Chronic kidney disease 20%
Heart failure 15%
RBC — red blood count; HGB — hemoglobin; HCT — hematocrit; WBC — white blood count; K+ — potassium; TSH — thyroid stimulating 
hormone; TC — total cholesterol; LDL — low density lipoprotein; HDL — high density lipoprotein; TG — triglycerides; CRP — C-reactive pro-
tein; BNP — B-type natriuretic protein; ALAT — alanine aminotransferase; Tn — troponin; PTCA — percutaneous transluminal coronary angio-
plasty; IFG — impaired fasting glucose; IGT — impaired glucose tolerance
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Table 2. Echocardiographic characteristics (before coronary-angiography).
Echocardiographic parameter Median Interquartile range 
Ejection fraction [%] 58.5 55–63
Right ventricular diastolic diameter [mm] 27 23–31
Interventricular septum diastolic diameter [mm] 12.5 12–15
Posterior wall diastolic diameter [mm] 11.5 10–12
Left ventricular end-diastolic diameter [mm] 45.5 44–48
Left atrium diameter [mm] 34.5 34–38
Diameter of aorta (valve ring) [mm] 19.5 19–23
Mitral flow rate, wave E [ m/s] 0.4 0.38–0.56
Mitral flow rate, wave A [m/s] 0.6 0.52–0.67
E/a’ 9.5 7–11
Deceleration time of E wave mitral flow [ms] 196.5 156–247
Isovolumetric relaxation time [ms] 118.5 104–133
Lateral wall, flow rate, wave e’ (tissue Doppler) [m/s] 0.05 0.04–0.07 
Lateral wall, flow rate, wave a’ (tissue Doppler) [m/s] 0.07 0.05–0.08
Acceleration time of right ventricular outflow [ms] 121 104–133
Table 3. Characterization and quantification of circulating endothelial cells (CEC) in the radial artery be-
fore angiography, and after coronary angiography/angioplasty from the radial artery and brachial vein. 
Parameter Before angiography  
(artery A1)
After angiography  
(artery A2)
After angiography  
(vein)
CEC/mL 63.9 (35.8–91.2) 99.1 (49.8–189.9)* 123.0 (28.4–299.2)
CEC per 106 PMNC 23.4 (13.0–32.4) 42.1 (22.8–61.9)** 58.5 (9.8–95.3)#
mvCEC/mL 28.9 (13.3–47.8) 26.2 (9.8–43.0) 51.2 (16.4–107.8)
mvCEC% of total CEC 53.5 (34.0–78.3) 23.2 (11.2–44.8)*** 41.4 (14.5–77.6)$ 
Data are shown as median (interquartile range). Arterial 1 vs. arterial 2: *p < 0.005, **p < 0.05, ***p < 0.05; Arterial 1 vs. vein: #p < 0.05; 
Arterial 2 vs. vein: $p < 0.05
Table 4. The comparison between subjects who had percutaneous transluminal coronary angioplasty 
(PTCA) performed vs those who did not have the operation performed. 
Parameter Patients without PTCA  
before angiography
Patients with PTCA performed  
before angiography
Artery A1 Artery A1
CEC/mL 255.5 (85.5–425.5) 63.4 (35.7–87.4) 
CEC per 106 PMNC 48.6 (28.8–68.5) 21.1 (12.4–27.9)
mvCEC/mL 90.5 (46.1–135) 36.5 (16.5–49.5) 
mvCEC% to CEC [%] 53.8 (31.1–76.4) 55.9 (43.3–80)
Artery A2 Artery A2
CEC/mL 401.8 (53.9–749.7) 88.7 (33.6–188.6)
CEC per 106 PMNC 73.5 (20.6–126.4) 42 (19.9–61)
mvCEC/mL 92.5 (44.4–140.6) 25 (8.8–42.2)
mvCEC% to CEC [%] 50.6 (19.3–81.2) 30.2 (14.6–45) 
Vein Vein
CEC/mL 403 (72.1–734) 135.3 (34.8–230.8) 
CEC per 106 PMNC 62 (33.4–90.6) 61.1 (9.6–100)
mvCEC/mL 160.6 (55.4–265.8) 53 (24.8–73.5)
mvCEC% to CEC [%] 56.4 (35.4–77.3) 46.1 (24.1–77.8)
Data are shown as median (interquartile range). P = not significant. CEC/ml — CEC per mL of peripheral blood; PMNC — CEC per 106 peripheral 
mononuclear blood cells, mvCEC/mL — CD36+ per mL of peripheral blood, %mvCEC to CEC — the CD36+ to all CEC per ml of peripheral blood
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angiography in artery and after angiography in 
vein) did not change significantly between patients 
who underwent PTCA and those who didn’t. Proper 
analysis of dependent samples in the mentioned 
groups were unable to perform due to small number 
of subjects (only group comparisons were done).
Coronary angiography characteristics and 
its potential influence on CEC counts
In 1 patient a myocardial bridge, which sig-
nificantly narrowed the left descending artery, 
was found. He did not have PTCA performed. 
One patient was diagnosed with severe coronary 
atherosclerosis and was qualified for acute surgi-
cal coronary artery by-pass grafting procedure, so 
no PTCA performed. Another subject showed no 
significant coronary stenosis. In this case PTCA 
was also not performed, but from the clinical data 
it was possible to diagnose takotsubo cardiomyopa-
thy. Angioplasty with implantation of 2 drug-eluting 
stents was performed in 2 patients. Long-lasting 
(58, 50, 40 min) and very complicated PTCA took 
place in 3 patients. High values of myocardial 
necrosis-troponin released markers were observed 
in 6 patients (25000, 6580, 5904, 4244, 3280, 2645 
ng/mL). In 1 patient, no reflow phenomenon was 
observed after angioplasty. In another patient, ad-
ditional severe aortic stenosis was observed but 
PTCA had not been performed.
Circulating endothelial cells and clinical data
Total CECs and CD36+ mvCEC were associ-
ated with individual clinical parameters. The ratio 
of CD36+ to all CEC per ml in arterial blood before 
angiography correlated with hemoglobin level (r = 
= 0.61) and reversely correlate with mean platelet 
volume (MPV; r = –0.78). MPV was positively 
correlated with CEC count (r = 0.57). CD36+ in 
arterial blood before angiography correlated with 
high density lipoprotein (r = 0.6), and reversely 
with triglycerides (r = 0.6). 
In arterial blood after coronary angiography/
angioplasty: CEC count was correlated with sodium 
and creatinine concentration (r = 0,49, r = 0.52, 
respectively), CD36+ with creatinine and white 
blood count (r = 0.49, r = –0.55, respectively. In 
vein blood CEC count was reversely correlated 
with total cholesterol and low density lipoprotein (r 
= –0.63, r = –0.063, respectively). Venous CD36+ 
were positively correlated with platelets (r = 0,49) 
and reversely correlated with MPV (r = –0.56), 
Total CECs and CD36+ mvCEC were also associ-
ated with various echocardiographic markers of 
LV relaxation dysfunction. However, due to weak 
correlation and lack of repeatability, these results 
were not provided. 
Discussion
Circulating endothelial cells were identified and 
described for the first time in the 1970s. However, 
available literature is ambiguous in several key is-
sues [8, 14]. In the beginning, there was no clear 
definition of the term “circulating endothelial cells” 
[15]. Discrepancies in the definition of CECs were 
caused by a lack of the consensus on the nature of 
specific surface antigens, as well as what the size 
and shape of isolated particles/cells needed to be [8]. 
For these reasons, results obtained from individual 
authors significantly differed one from another [14].
After finding consensus on phenotypic char-
acteristics specific to the CECs (CD146+, CD31+, 
CD36+), another source of variability between 
different studies was caused by the different tech-
nologies used for identification and quantification of 
these cells [8, 15–17]. Immunomagnetic methods 
allowed for isolation of cells on the basis of one 
specified surface antigen, therefore with less of 
specificity than compared to flow cytometry, which 
can use several different fluorescent-active anti-
bodies. Moreover, most of the studies aimed only to 
quantify circulating cells rather than qualitatively 
analyze them [16–20]. 
The presence of CECs in the bloodstream 
is a physiological phenomenon resulting from 
impaired adhesive interactions between the base-
ment membrane and endothelium [8, 14, 15]. 
The observed increase in the number of CECs is 
caused by a temporary impairment of the adhesive 
homeostasis by mechanical injury, apoptosis or 
necrosis [8, 14, 15]. Moreover, released CECs have 
different phenotypes depending on the activation 
properties, mode of their release (necrosis, apop-
tosis, mechanical damage) or their vascular origin. 
The most important factors which contribute to 
pathogenesis of CECs production are myocardial 
ischemia, inflammation, diabetes as well as thyroid 
or renal disturbances [21]. In the present study  no 
significant CEC association with dysglicemia was 
observed, dyslipidemia with reduced LV ejection 
fraction or hypertension was also not observed. 
There were also no quantitative and phenotypic dif-
ferences in CEC isolated from arterial and venous 
blood samples among patients with dysglicemia, 
dyslipidemia and reduced ejection fraction. Never-
theless, proper statistical analysis was not possible 
due to the small group and large heterogeneity of 
the cohort. 
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Literature data shows that the number of 
CECs detected in the arterial system or venous 
system are similar, while there is no data concern-
ing CEC phenotype differences between these 
compartments [8, 14, 15]. The goal herein, was to 
compare the number and type of cells present in 
the arterial system after angiography/angioplasty, 
and 30 min after an invasive procedure from the 
venous system. It was found that the total num-
ber of CEC cells isolated at similar time points 
did not differ significantly between arterial and 
venous compartments. Little variation in CEC 
count was probably due to different time points 
of cell isolation (30 min delay between arterial 
and venous blood collection), rather than differ-
ences between these vascular compartments. A 
significantly higher number of cells with CD36+ 
phenotype was observed in the venous system 
when it was compared to artery samples (before or 
after angiography/angioplasty). This was the only 
difference between arterial and venous systems in 
the context of isolated endothelial cells, that hadn’t 
been described previously in the literature. 
In the studied cohort, the total number of 
CECs detected in the blood before angiography 
was lower than the number of CECs obtained 
after angiography/angioplasty from both arterial 
and venous system. It may be speculated that this 
confirms results of other authors and possible 
cause of the phenomenon is increased CEC release 
after mechanical injury during angioplasty [8, 14, 
15]. There was no such observation in those who 
had not been treated with PTCA. The number of 
CECs was high at baseline and in the following 
time it was increasing, but not significantly. It may 
be speculated, that it could be explained rather by 
chronic myocardial ischemia which leads to low 
or moderate CECs increase, than other causes. 
However, absolute variability of the CECs number 
between patients who had vs. those who had not 
been treated with PTCA was not relevant.
This pilot study also aimed to find various 
sources of CEC. In subjects with clinically relevant 
ischemia (according to ESC ACS guidelines) ac-
companied by clinical probability of microcircula-
tory disturbances represented by diastolic dysfunc-
tion which were hoped to collect CEC originated 
from different vascular beds. It was found and dis-
tinguished that CD36+ from CD36–. There were no 
significant differences in the number of CD36+ in 
various blood collection time points. Interestingly, 
the number of CD36+ in artery samples obtained 
after coronary angioplasty (PTCA) had  tended to 
be decreased (in comparison to samples obtained 
before angiography). The CD36+ in following 
blood samples tended to be increased in patients 
who had no angioplasty performed. There was 
major difference between those who had PTCA 
performed vs. those who had not. This phenome-
non  could not be properly explained. It is possible 
that it may have been a chance  result. Secondly, it 
may only be speculated that angioplasty preserves 
blood supply to the myocardium and also improves 
homeostasis of microcirculation, which reduces 
the unpleasant effect of ischemia and diminishes 
CEC release. Patients without PTCA had their 
ischemia not reversed (complex epicardial and 
microcirculatory ischemia), and could explain the 
CD36+ increase.
The clinical application of this study is that 
isolation and determination of CEC phenotype is 
possible and that angioplasty of the epicardial coro-
nary artery may influence the profile of released 
endothelial cells. Further studies on quantitative 
CEC properties are required, the purpose is to al-
low better distinction in angina subjects and those 
with impaired coronary microcirculation.
Limitations of the study
Due to a very small size of the group studied 
and the fact that statistical analysis cannot be per-
formed for some parameters, results of the project 
should be interpreted as descriptive statistics. 
Another limitation was that the CEC results were 
not compared to other clinical groups of patients 
(i.e. healthy volunteers), which however was 
not a primary endpoint of the project’s plan. The 
purpose of the study was confirmation of the no-
tion that CEC count’s variability depends on their 
vascular origin. It is worth noting that although 
the study group was small due to the highly selec-
tive inclusion criteria, its undoubted advantage is 
its homogeneity (according to various sources of 
CEC). The blood was obtained from patients with 
suspected coronary microvascular disturbances 
and hemodynamic decompensation due to con-
comitant changes in the epicardial artery during 
the course of NSTEMI. Such groups with various 
sources of CEC in average patients have, as of yet, 
not been described in the literature.
Finally, there are no known markers that can 
be used to distinguish CECs derived from coro-
nary microcirculation from other microcirculation 
locations. That is why, they were excluded from 
patients studied having suspected peripheral artery 
disease of any kind. The phenotypic features that 
differentiate CEC from various micro-circulating 
beds are a separate subject of interest.
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Conclusions
The number of CECs after PTCA increased 
significantly in the arterial system. In the venous 
system, although the observed CEC cell numbers 
were the highest, differences were not statistically 
significant.
The number of cells with CD36+ phenotype 
after coronary angioplasty did not change signifi-
cantly in the arterial system, but was significantly 
higher in vein, although the blood was collected 
during a similar period following an invasive cardiac 
procedure.
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